BCR was observed in 1293 patients with PCa, including 697 low-risk and 596 intermediate-risk patients who underwent HDR-BT or LDR-BT monotherapy, C-RT, or moderate H-RT [88]. This evidence concerns the gene BCR and posterior cortical atrophy.